Pontifax reports 1.41M indirect LBRX shares after conversion and purchase
Rhea-AI Filing Summary
Pontifax Management 4 G.P. (2015) Ltd. reported purchases and conversions of LB Pharmaceuticals Inc. securities on 09/12/2025. The filing shows an automatic conversion of 10,000,000 shares of Series C preferred stock into common stock immediately prior to the issuer's IPO closing, and the reporting person acquired 411,681 shares of common stock via conversion. In a separate transaction the reporting person purchased 1,000,000 shares of common stock at $15.00 per share, bringing total beneficial ownership reported to 1,411,681 shares on an indirect basis through affiliated Pontifax entities. The form is signed by the issuer's CFO on 09/16/2025.
Positive
- Clear disclosure of conversion of 10,000,000 Series C preferred shares into common stock immediately prior to IPO closing
- Large open-market purchase of 1,000,000 common shares at a specified price of $15.00 per share
- Beneficial ownership broken out by Pontifax Israel and Pontifax Cayman with totals provided
Negative
- Filing shows indirect ownership only; direct voting power and any specific voting arrangements are not detailed beyond general partner relationships
- No forward-looking information or rationale provided for the $15.00 purchase, limiting context for investors
Insights
TL;DR: Insider group increased indirect ownership via conversion and a $15 stock purchase totaling 1,411,681 common shares.
The filing documents two material events: automatic conversion of 10,000,000 Series C preferred into common equity tied to the IPO mechanics, and an affirmative market purchase of 1,000,000 common shares at $15.00. Together these actions consolidate the Pontifax entities' indirect stake reported as 1,411,681 shares. For investors, this clarifies insider holdings post-IPO and the notional cash price for a substantial block; it does not provide operating results or forward guidance.
TL;DR: The report discloses standard post-IPO conversion mechanics and an affiliated purchaser increasing indirect holdings.
The disclosure identifies the reporting structure of Pontifax Israel and Pontifax Cayman and notes that Pontifax Management is the general partner, with named managing partners who may share voting and investment power. The filing is complete regarding transaction types, amounts, and the $15 purchase price, and it includes the required signature. No departures, option grants, or governance changes are reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series C Preferred Stock | 10,000,000 | $0.00 | -- |
| Conversion | Common Stock | 411,681 | $0.00 | -- |
| Purchase | Common Stock | 1,000,000 | $15.00 | $15.00M |
Footnotes (1)
- Each share of Series C Preferred Stock automatically converted immediately prior to the closing of the Issuer's initial public offering for no additional consideration at a conversion ratio that was dependent upon the initial price per share to the public in the Issuer's initial public offering. Consists of (i) 261,938 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 149,743 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Consists of (i) 636,263 shares of common stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 363,737 shares of common stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities. Consists of (i) 6,362,625 shares of our redeemable convertible preferred stock held by Pontifax (Israel) VI Limited Partnership, or Pontifax Israel, and (ii) 3,637,375 shares of our redeemable convertible preferred stock held by Pontifax (Cayman) VI Limited Partnership, or Pontifax Cayman. Pontifax Israel and Pontifax Cayman are collectively referred to as the Pontifax Entities. Pontifax VI G.P. L.P., or Pontifax VI G.P., is the general partner of each of the Pontifax Entities and Pontifax Management IV G.P. (2015) Ltd., or Pontifax Management, is the general partner of Pontifax VI G.P. Messrs. Tomer Kariv and Ran Nussbaum, are the Managing Partners of Pontifax Management and, as a result, may be deemed to share voting and investment power with respect to the shares held by each of the Pontifax Entities.
